Neximmune Stock Alpha and Beta Analysis

NEXI Stock  USD 0.0001  0.00  0.00%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Neximmune. It also helps investors analyze the systematic and unsystematic risks associated with investing in Neximmune over a specified time horizon. Remember, high Neximmune's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Neximmune's market risk premium analysis include:
Beta
0.0
Alpha
0.0
Risk
0.0
Sharpe Ratio
0.0
Expected Return
0.0
Please note that although Neximmune alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Neximmune did 0.00  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Neximmune stock's relative risk over its benchmark. Neximmune has a beta of 0.00  . The returns on DOW JONES INDUSTRIAL and Neximmune are completely uncorrelated. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Neximmune Backtesting, Neximmune Valuation, Neximmune Correlation, Neximmune Hype Analysis, Neximmune Volatility, Neximmune History and analyze Neximmune Performance.

Neximmune Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Neximmune market risk premium is the additional return an investor will receive from holding Neximmune long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Neximmune. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Neximmune's performance over market.
α0.00   β0.00

Neximmune expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Neximmune's Buy-and-hold return. Our buy-and-hold chart shows how Neximmune performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Neximmune Market Price Analysis

Market price analysis indicators help investors to evaluate how Neximmune pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neximmune shares will generate the highest return on investment. By understating and applying Neximmune pink sheet market price indicators, traders can identify Neximmune position entry and exit signals to maximize returns.

Neximmune Return and Market Media

The median price of Neximmune for the period between Fri, Oct 10, 2025 and Thu, Jan 8, 2026 is 1.0E-4 with a coefficient of variation of 0.0. The daily time series for the period is distributed with a sample standard deviation of 0.0, arithmetic mean of 0.0, and mean deviation of 0.0. The Stock did not receive any noticable media coverage during the period.
 Price Growth (%)  
       Timeline  

About Neximmune Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Neximmune or other pink sheets. Alpha measures the amount that position in Neximmune has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Neximmune Upcoming Company Events

As portrayed in its financial statements, the presentation of Neximmune's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neximmune's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Neximmune's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Neximmune. Please utilize our Beneish M Score to check the likelihood of Neximmune's management manipulating its earnings.
26th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View

Build Portfolio with Neximmune

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Other Information on Investing in Neximmune Pink Sheet

Neximmune financial ratios help investors to determine whether Neximmune Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Neximmune with respect to the benefits of owning Neximmune security.